Cell Therapy Market Size To Reach USD 97 Billion By 2033

The global cell therapy market reached USD 14.52 billion in 2023 and is projected to surpass around USD 97 billion by 2033, poised to grow at a CAGR of 20.9% from 2024 to 2033.

Key Points

North America led the global market with the highest market share of 53.14% in 2023.
Asia Pacific region is estimated to expand the fastest CAGR of 16% between 2024 and 2033.
By user type, the research use segment registered a maximum market share of 62.30% in 2023.
By user type, the clinical use segment is anticipated to grow at a remarkable CAGR of 13.5% between 2024 and 2033.
By therapy type, the autologous therapies segment generated over 56% of revenue share in 2023.

The governments all over the world are constantly investing in the biopharmaceutical industry’s development. This has a direct impact on the worldwide cell therapy market’s growth. For the introduction of innovative cell treatments into the worldwide market, leading industry participants are partnering with government authorities.

Get the Sample Pages of Report@ https://www.precedenceresearch.com/sample/1700

Furthermore, for the growth and development of the global cell therapy market, industry participants are focusing on existing and developing areas. The high cost of cell therapies, on the other hand, is a major impediment to the worldwide cell therapy market’s expansion. Furthermore, the cell treatment market’s expansion is hampered by a scarcity of experienced personnel. However, due to the vast range of applications for cell therapy, the worldwide cell therapy market is likely to rise rapidly in the near future.

Regional Snapshot

North America is the largest segment for cell therapy market in terms of region. The U.S. is dominating the cell therapy market in the North America region. For the development of the cell therapy industry, variables such as rising chronic disease occurrences and increasing investments are important. Furthermore, expanding uses of stem cell technology for the treatment of various ailments are propelling the cell therapy market in North America. In addition, the market for cell treatment in North America is rising due to increased research and development activities.

Asia-Pacific region is the fastest growing region in the cell therapy market. China holds the highest market share in the Asia-Pacific cell therapy market. The expansion of the cell therapy market in this region is aided by favorable government policies. In addition, as a result of enhanced healthcare facilities, reduced costs, and rise in awareness of cell therapy, growing nations are expected to rise.

Report Highlights

On the basis of user type, research use segment holds the largest market share in the global cell therapy market. Cell treatment is commonly employed in scientific studies. The segment’s expansion is being fueled by an increase in research and development projects. Furthermore, important industry participants are heavily spending in research programs. Not only are market participants participating in research projects, but government organizations are also partnering on cell-based research.
On the basis of therapy type, autologous therapies segment holds the largest market share in the global cell therapy market. The increased usage of autologous therapies on a large scale is credited for the segment’s rise. Furthermore, when compared to allogenic therapies, autologous therapies are very cost effective. As a result, this element is propelling the segment forward.

Table of Contents

Cell Therapy Market Scope

Report Coverage	Details
Growth Rate from 2024 to 2033	CAGR of 20.9%
Market Size in 2023	USD 14.52 Billion
Market Size by 2033	USD 97 Billion
North America Market Share in 2023	53.14%
Research Use Segment Market Share in 2023	62.30%
Base Year	2023
Forecast Period	2024 to 2033
Segments Covered	By Use Type, By Therapy Type, and By End User
Regions Covered	North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Cell Therapy Market Dynamics

Drivers

Growing approvals for cell-based therapies

The cell therapies are getting approved easily by government agencies. Since FDA approved products are readily available in developing regions, cell treatments are commonly used. For example, the FDA granted Novartis’ Kymriah regenerative medicine enhanced therapy designation in April 2020 for the treatment of refractory follicular lymphoma in adults. The FDA authorized brexucabtagene autoleucel, a CAR T-cell treatment for patients with mantle cell lymphoma in July 2020.

Restraints

High capital investments for cell therapy plants

People seeking the most up to date alternative remedies for the various ailments have become increasingly interested in stem cell therapy nowadays. Every day, new sorts of therapies are launched and individuals all over the globe are turning to them instead of standard drug regimens and hospital visits. Despite the high demand for stem cell therapies, they are still prohibitively costly to develop. Simple joint injections can set back about $1,000 while more complex procedures can cost up to $100,000 depending on the issue.

Opportunities

Growing government initiatives

The government is heavily investing in research and development activities. The Australian government published The Stem Cell Therapies Mission, journey of 10 years for stem cell research, in November 2019. The Medical Research Future Fund would receive $102 million to support stem cell research in order to develop novel medicines. Thus, the growing government initiatives are creating lucrative opportunities for the growth of global cell therapy market.

Challenges

Lack of skilled professionals

The lack of skilled professionals is a major challenge faced by global cell therapy market. As per the National Accrediting Agency for Clinical Laboratory Sciences, there is a global demand supply mismatch for competent personnel. According to a research study conducted by the Gatsby Foundation, the UK will require an additional 700,000 professionals to sustain the economy by 2030.

Recent Developments

Miracell, a Korean stem cell therapy company, will enter the Middle East market in March 2022 after achieving success in Europe. According to the company’s CEO, the afternoons are entirely booked with teleconference with possible Middle Eastern buyers. Miracell is a stem cell therapy and cell banking company that was founded in 2009.
KIMMTRAK Immunocore’s treatment for advanced and metastatic uveal melanoma was approaved by the FDA in January 2022.
Thermo Fisher Scientific declared the release of comprehensive and integrated commercial packaging and distribution services in February 2022, designed to help patients across the U.S. and Europe transition from clinic to commercial release. Patheon Commercial Packaging Services is a new end to end solution for programmers that combine worldwide distribution and serialization to assist their logistics strategy.

Cell Therapy Market Companies

Kolon TissueGene Inc.
JCR Pharmaceuticals Co. Ltd
Castle Creek Biosciences Inc.
Anterogen Co. Ltd
The Future of Biotechnology
Celgene Corporation
Tameika Cell Technologies Inc.
Cells for Cells
MEDIPOST
NuVasive Inc.

Segments Covered in the Report

By Use Type

Clinical use
- By Therapeutic Area
  - Malignancies
  - Muscoskeletal Disorders
  - Autoimmune Disorders
  - Dermatology
  - Cardiovascular
  - Ocular
  - Wounds and injuries
  - Others
- By Cell Type
  - Stem Cell Therapies
  - BM, Blood, & Umbilical cord-derived Stem Cells
  - Adipose-derived cells
  - Others
- Non-stem Cell Therapies
Research use

By Therapy Type

Autologous Therapies
Allogenic Therapies

By End User

Hospitals
Diagnostic centers
Clinics
Research institutes
Regenerative medicine centers
Others

By Technology

Viral Vector Technology
Genome Editing Technology
Somatic Cell Technology
Cell Immortalization Technology
Cell Plasticity Technology
Three-dimensional Technology

By Geography

North America
- U.S.
- Canada
Europe
- U.K.
- Germany
- France
Asia-Pacific
- China
- India
- Japan
- South Korea
- Malaysia
- Philippines
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC
- North Africa
- South Africa
- Rest of the Middle East & Africa